Aegerion Pharmaceuticals (NAS: AEGR) has received its first approval from the Food and Drug Administration, the company announced in a press release. The FDA gave the nod to the firm's Juxtapid, a drug that combats a rare genetic cholesterol disorder called homozygous familiar hypercholesterolemia.

According to The Wall Street Journal, around 3,000 patients in the U.S. are eligible to use the medication. It is expected to cost $200,000-$300,000 per year for a prescription. Since Juxtapid carries a risk of liver toxicity, the FDA is requiring the company to ship it with warning labels addressing that fact.

Aegerion will begin the sales process for Juxtapid in January.

The article FDA Approves Aegerion Cholesterol Drug originally appeared on

Eric Volkman has no positions in Aegerion Pharmaceuticals, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Increase your money and finance knowledge from home

Investing in Startups

The lucrative and risky world of startups.

View Course »

Forex for Beginners

Learn about trading currencies and foreign exchange transactions

View Course »

Add a Comment

*0 / 3000 Character Maximum